Physician

Abdul R Effendi, MD

According to 2025 Medicare claims, Abdul Effendi, MD (NPI: 1881647584) practices nephrology in the Warren-Troy-Farmington Hills, MI market, with the plurality of this provider's patient population coming from Macomb, MI. This provider's primary affiliated billing organization is KIDNEY CONSULTANTS OF MICHIGAN PC (NPI: 1932396496; TIN: 383581514) and primary practice location at 48085-1117. Effendi is affiliated with the Arvon CIN (ACO ID: A1095), participating under the MSSP model.

Effendi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 983 traditional Medicare patients, billed 5,800 HCPCS/CPT codes, and received $459,166 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 7,023 prescription claims across 849 beneficiaries totaling $2,449,445 in drug costs, led by Jardiance (Empagliflozin). DME data shows 52 claims. Open Payments data shows 35 records totaling $969. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $509,265 to $2,449,445. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $1,563 to $2,830.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	923	4,548	$381,953
2016	809	4,540	$344,443
2017	807	5,047	$340,679
2018	786	25,093	$324,206
2019	826	24,972	$316,723
2020	770	26,523	$320,034
2021	598	19,876	$210,647
2022	693	4,257	$262,487
2023	701	8,165	$291,719
2024	983	5,800	$459,166

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	305	3,231	$509,265
2016	295	2,858	$420,032
2017	303	2,532	$331,348
2018	304	2,945	$236,867
2019	367	3,230	$313,801
2020	325	3,238	$425,498
2021	345	2,890	$417,357
2022	474	4,253	$1,124,151
2023	546	4,491	$1,629,957
2024	849	7,023	$2,449,445

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	161	$12,837
2016	N/R	153	$11,586
2017	N/R	192	$11,833
2018	N/R	205	$10,031
2019	N/R	192	$7,760
2020	N/R	182	$9,202
2021	N/R	85	$3,784
2022	N/R	66	$4,381
2023	N/R	32	$1,181
2024	N/R	52	$1,510

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	304	360	$105
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	315	968	$94
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	406	934	$80
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	411	2,155	$63
36415	Insertion of needle into vein for collection of blood sample	252	496	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	484	22,651	$429,635
Ozempic	Semaglutide	350	13,454	$410,033
Farxiga	Dapagliflozin Propanediol	398	21,032	$369,971
Kerendia	Finerenone	167	9,040	$185,708
Mounjaro	Tirzepatide	166	5,052	$179,213

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	20	$1,027
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	21	$358
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$125

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	35	$969	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abdul R. Effendi, MD?

Tedicare shows public-source Medicare data for Abdul R. Effendi, MD (NPI 1881647584), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abdul R. Effendi, MD have ACO affiliation data?

Abdul R. Effendi, MD is shown with ACO affiliation data for Arvon CIN (MSSP, ACO ID A1095).

What billing organization is linked to Abdul R. Effendi, MD?

Abdul R. Effendi, MD is linked to KIDNEY CONSULTANTS OF MICHIGAN PC (billing NPI 1932396496) in the available physician profile data.

Does Abdul R. Effendi, MD have Open Payments data?

Abdul R. Effendi, MD has 35 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.